Cures Within Reach Releases CureAccelerator™ v2.0
Rallies Researchers and Clinicians to Meet 100 New Projects Goal
SKOKIE, Ill. - March 8, 2016 - PRLog -- Cures Within Reach (www.cureswithinreach.org)
“We are already seeing exciting repurposing research treatments move into clinical testing as a result of the collaboration among researchers, clinicians and funders on CureAccelerator,”
CureAccelerator v2.0 enhancements include improved navigation throughout the platform via a customized user dashboard that displays the funding amount, funding stage, project stage and remaining amount to be funded, with a link to a crowdfunding page for partially funded projects. An improved search function, ability to sort projects by funding status and other new functions also have been added.
To expand the repurposing research community beyond researchers, clinicians and philanthropic funders, a company representative user category has been added to support industry participation, both as funders and collaborators. Integrated scientific review will also be in this release, so that current users and non-users can be invited to become scientific reviewers for a specific proposal.
These new enhancements come on the heels of Cures Within Reach’s successful effort to secure 100 new repurposing research projects on CureAccelerator during the early part of 2016. Since the platform launched in May 2015, it has hosted more than 100 repurposing research projects from among 729 users. The recently secured projects were initiated from 52 research institutions in 7 countries. The projects proposed repurposed treatments for a wide variety of diseases, including 35 in oncology, 18 addressing neurology/neurodegenerative concerns and 19 in pediatric or rare diseases.
“As part of our effort to secure 100 new projects on CureAccelerator during the early part of 2016, we conducted site visits to research institutions across the country to learn about their efforts in repurposing research. We found that there is a great deal of excitement about repurposing as a way to treat diseases,” said Clare Thibodeaux, Director of Scientific Affairs at Cures Within Reach. “We hope our work and resources will help encourage researchers and clinicians and their institutions to bring even more energy and expertise to repurposing research.”
ABOUT CURES WITHIN REACH
Cures Within Reach (www.cureswithinreach.org)
Cures Within Reach’s repurposing research projects have generated 13 “new” treatments making an impact in the following diseases through off-label use in clinical practice or through a commercialization track: autoimmune lymphoproliferative syndrome, familial dysautonomia, Types 1 and 2 diabetes, lung cancer, multiple sclerosis, non-Hodgkin’
The organization built CureAccelerator (www.cureaccelerator.org)
Visit us at www.cureswithinreach.org or follow us via Twitter.com/
“We are already seeing exciting repurposing research treatments move into clinical testing as a result of the collaboration among researchers, clinicians and funders on CureAccelerator,”
CureAccelerator v2.0 enhancements include improved navigation throughout the platform via a customized user dashboard that displays the funding amount, funding stage, project stage and remaining amount to be funded, with a link to a crowdfunding page for partially funded projects. An improved search function, ability to sort projects by funding status and other new functions also have been added.
To expand the repurposing research community beyond researchers, clinicians and philanthropic funders, a company representative user category has been added to support industry participation, both as funders and collaborators. Integrated scientific review will also be in this release, so that current users and non-users can be invited to become scientific reviewers for a specific proposal.
These new enhancements come on the heels of Cures Within Reach’s successful effort to secure 100 new repurposing research projects on CureAccelerator during the early part of 2016. Since the platform launched in May 2015, it has hosted more than 100 repurposing research projects from among 729 users. The recently secured projects were initiated from 52 research institutions in 7 countries. The projects proposed repurposed treatments for a wide variety of diseases, including 35 in oncology, 18 addressing neurology/neurodegenerative concerns and 19 in pediatric or rare diseases.
“As part of our effort to secure 100 new projects on CureAccelerator during the early part of 2016, we conducted site visits to research institutions across the country to learn about their efforts in repurposing research. We found that there is a great deal of excitement about repurposing as a way to treat diseases,” said Clare Thibodeaux, Director of Scientific Affairs at Cures Within Reach. “We hope our work and resources will help encourage researchers and clinicians and their institutions to bring even more energy and expertise to repurposing research.”
ABOUT CURES WITHIN REACH
Cures Within Reach (www.cureswithinreach.org)
Cures Within Reach’s repurposing research projects have generated 13 “new” treatments making an impact in the following diseases through off-label use in clinical practice or through a commercialization track: autoimmune lymphoproliferative syndrome, familial dysautonomia, Types 1 and 2 diabetes, lung cancer, multiple sclerosis, non-Hodgkin’
The organization built CureAccelerator (www.cureaccelerator.org)
Visit us at www.cureswithinreach.org or follow us via Twitter.com/
End
| Tags | : | Repurposing Research, Drug Repurposing, Rare Diseases |
|---|---|---|
| Industry | : | Health |
| Location | : | Skokie - Illinois - United States |
| Subject | : | Products |